Page 27 - Wondergem

45. Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and 1 transformed Non-Hodgkin’s lymphoma: results from a phase II multicenter, single agent study. J Clin Oncol.
2008;26:204-210
46. Friedberg JW, Mahadevan D, Cebula E et al. Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell Non-Hodgkin Lymphomas. J Clin Oncol. 2013;32:44-50
47. Guirguis HR, Cheung MC, Piliotis E et al. Survival of patients with transformed lymphoma in the rituximab era. Ann Hematol. 2014;93:1007-1014
48. Kraut EH, Balcerzak SP, Young D et al. A phase II study of topotecan in non-Hodgkin’s lymphoma: an Ohio State University phase II research consortium study. Cancer Investigation 2002;20(2):174-179
49. Ogura M, Ando K, Taniwaki M et al. Feasability and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Cancer Sci 2011;102:1687-1692
50. Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine fosfate in lymphoma: an effective new agent in low grade lymphoma. J Clin Oncol 1992;10:790-794
51. Vose JM, Habermann TM, Czuczman MS et al. Single agent lenalidomide is active in patients with relapsed or refractory aggressive non Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol.2013;162(5): 639-647
52. Wang M, Fowler N, Wagner Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular or transformed lymphoma: a phase II clinical trial. Leukemia 2013:27(9):1902-1909
53. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol 2011;22:1622-1627
54. Wiernik PH, Lossos IS, Tuscano JM. Lenalidomide monotherapy in relapsed or refractory aggressive non- Hodgkin’s lymphoma. J Clin Oncol 2008;26:4952-4957
55. Aydin S, Duhrsen U, Nuckel H. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single centre study of 20 patients. Ann Hematol. 2007;86:271-276
56. Jermann M, Jost LM, Taverna Ch, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004;15:511-516
57. Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995;13:1734-1741
58. Buchegger F, Antonesco C, Helg C, et al. Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131-tositumomab remain in complete remission. J Nucl Med 2011;52: 896-900
59. Davies AJ, Rohatiner AZS, Howell S et al. Tositumomab and Iodine I 131 Tositumomab for recurrent indolent and transformed B-cell Non-Hodgkin’s lymphoma. J Clin Onclol 2004;22:1469-1479
60. Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine 131I Tositumomab for relapsed or refractory B-cell non Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-1266.
61. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of Iodine I131 Tositumomab for chemotherapy- refractory low-grade or transformed lo-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2001;19:3918- 3928
62. Kaminski MS, Zasadny KR, Francis IR et al. Iodine 131 anti B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-1981
63. Linden O, Tennvall J, Hindorf C et al. 131I-labelled anti CD22 Mab (LL2) in patients with B-cell lymphomas failing chemotherapy. Acta Oncol. 2002;41:297-303
64. Vose JM, Wahl RL, Saleh M et al. Multicenter Phase II study of Iodine-131-tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2000;18:1316-1323
65. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of Yttrium-90-labelled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453-2463
66. Briones J, Novelli S, Garcia-Marco JA et al. Autologous stem cell transplantation after conditioning with Yttrium-90-ibritumomab tiuxetan plus BEAM in refractory B-cell non-Hodgkin diffuse large B cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica 2014;99(3): 505-510
Introduction and scope of this thesis
25